68Ga-PSMA-11 PET accuracy in recurrent prostate cancer

Telo, Silvi; Farolfi, Andrea; Castellucci, Paolo; Fanti, Stefano

doi:10.21037/tau.2019.07.13

Cited by 5 publications

(4 citation statements)

References 15 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nuclear medicine imaging is a safe and non-invasive technique used especially in patients with biochemical recurrence (BR), which is commonly assessed based on a rising PSA level [ 3 ]. Choline-based radiotracers have been used for years in PCa imaging; however, sometimes they have a limited value for identifying local recurrence, benign prostatic hyperplasia (BPH), and lymph nodes [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Imaging in prostate cancer plays a pivotal role in staging and determining the extent of the disease. Among the available imaging modalities are magnetic resonance imaging (MRI), transrectal ultrasonography (TRUS), and positron emission tomography/computed tomography (PET/CT) with radiotracers showing avidity to the prostate gland, choline-based radiotracers ([ 11 C]MET, [ 18 F]FCH), [ 18 F]fluciclovin) and radiolabeled prostate-specific membrane antigen (PSMA) ligands ([ 68 Ga]Ga-PSMA, [ 18 F]F-PSMA, [ 99m Tc]Tc-PSMA) [ 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [68Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy

et al. 2022

View full text Add to dashboard Cite

Objective: The objective of this study was to identify the optimal cut-off value of prostate specific antigen (PSA) to assess the extent of the disease in [68Ga]Ga-PSMA-11 PET/CT study in patients after radical prostatectomy. Materials and Methods: Retrospective analysis was performed on a group of 215 patients who underwent a [68Ga]Ga-PSMA-11 PET/CT examination because of suspected recurrence after radical prostatectomy. Patients were divided into four groups: 1, no active lesions suggesting recurrence (n = 92); 2, suspected isolated local recurrence (n = 19); 3, oligometastatic disease (n = 82); and 4, polymetastatic disease (n = 22). Results: In group 1, the mean PSA level was 0.962 ng/mL (median: 0.376; min: 0.004; max: 25 ng/mL); in group 2, it was 4.970 ng/mL (median 1.320; min: 0.003; max: 40.350 ng/mL); in group 3, it was 2.802 ng/mL (median: 1.270; min: 0.020; max: 59.670 ng/mL); and in group 4, it was 4.997 ng/mL (median: 3.795; min: 0.007; max 21.110 ng/mL). Statistically significant differences were shown in PSA levels when comparing groups 1 and 2 (p = 0.0025) and groups 3 and 4 (p = 0.0474). The PSA cut-off point for discriminating groups 1 and 2 was 0.831 (sensitivity: 0.684; specificity: 0.772; area under the curve (AUC): 0.775), and for groups 3 and 4, it was 2.51 (sensitivity: 0.682; specificity: 0.780; AUC: 0.720). Conclusions: Our preliminary data suggested that the PSA level has an essential influence on determining the extent of disease in a [68Ga]Ga-PSMA-11 PET/CT study in patients after radical prostatectomy. Identification of the optimal cut-off values for the oligo- and polymetastatic diseases might be helpful in stratifying these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [68Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, postponing SRT in favor of follow-up imaging may deprive those patients of the only curative treatment option. This situation is particularly problematic, because approximately 50% of patients remain PET-negative after they surpass the therapeutic window of 0.5 ng/ml [20,21]. Moreover, BR has been shown to impact OS in patients with low PSA-doubling times (<12 months) and/or high ISUP scores (4+5) [22].…”

Section: Wenzel Et Al Analyzed a Subgroup Of 90 Patients With Pet-neg...mentioning

confidence: 99%

Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study

Scharl

Zamboglou

Strouthos³

et al. 2023

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

“…Conventionally, BM in PC is mainly diagnosed using 99mTcbased bone scintigraphy, and recently 68 Ga-prostate-specific membrane antibody (68 Ga-PSMA) positron emission tomography/computed tomography (PET/CT) provided a major advance in the diagnosis and staging by adding functional information reflecting metabolic changes (18). In addition, 68 Ga-PSMA PET/CT images can detect BM earlier than CT or radionuclide bone scans and identify lesions in tissues other than the bone (19).…”

mentioning

confidence: 99%

Diagnosing and Prognosing Bone Metastasis in Prostate Cancer: Clinical Utility of Blood Biomarkers

et al. 2022

View full text Add to dashboard Cite

Bone metastasis (BM) may occur in any type of cancer. The diagnosis of patients with BM has increased due to improved imaging technologies and advances in cancer drug therapy that have prolonged the survival time of cancer patients. BM may be asymptomatic in the early stages; however, as the disease progresses, it causes pain, fracture, neurological symptoms associated with spinal cord compression, hypercalcemia, and other specific symptoms that significantly impair the patient's quality of life (QOL). Imaging modalities have disadvantages, such as high cost, radiation exposure, and bone pain associated with holding posture for imaging test; further, they are time-consuming. Hence, patients with BM require convenient and useful biomarkers. However, no blood biomarkers generally useful for diagnosis and therapeutic monitoring of BM are established. Prostate cancer (PC) and breast cancer, in particular, are among the most prone to BM because BM occurs in approximately 70% of patients with advanced disease. Herein, we reviewed various potential bone turnover markers and liquid biopsy for diagnosis and prognosis prediction in patients with BM of PC based on PubMed literature search. The usefulness of conventional bone turnover markers of BM in PC is limited, and cut-off values vary. In the future, the creation of algorithms using these conventional markers and multiple tests, such as liquid biopsy and imaging tests, will help to develop highly accurate techniques for the diagnosis of BM.The number of cancer survivors is increasing due to advances in medical technology, and an increase in effectively diagnosing patients with bone metastasis (BM) (1). The incidence of BM varies depending on the primary tumor type, with prostate cancer (PC) at highest risk of developing BM (85%), followed by lung cancer, kidney cancer, and breast cancer, and it is the lowest (13%) for colon cancer (2-4). Although prostate specific antigen screening and new advances in PC treatment improved survival, future projections indicate that by 2040, 379,000 people will die due to PC worldwide (5). Owing to the progression of systematic medical therapies, life expectancy and the number of patients with BM are increasing and will continue to do so (6). Generally, BM may cause skeletal related events (SRE), such as pain, fractures, spinal cord compressions, hypercalcemia, prolonged hospitalization period, and significantly reduce the quality of life (QOL) in patients with short prognosis (7). BM in patients with breast cancer is a mixed osteolytic and osteoblastic type, whereas in PC, it is predominantly osteosclerotic type. Bone metastatic sites of PC undergo osteogenic changes but are more brittle than normal bone (8). Thus, BM is a clinically important and distinctive condition; however, the American Society of Clinical Oncology guidelines state that there are no established bone turnover markers, effective for monitoring BM in clinical practice (9).In 1889, Paget proposed the seed and soil theory (10), in which cancer cells and remote organs of...

show abstract

68Ga-PSMA-11 PET accuracy in recurrent prostate cancer

Cited by 5 publications

References 15 publications

Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [68Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy

Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [68Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy

Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study

Diagnosing and Prognosing Bone Metastasis in Prostate Cancer: Clinical Utility of Blood Biomarkers

Contact Info

Product

Resources

About